CX‐5461 is a novel selective RNA polymerase I (Pol I) inhibitor. Previously, we found that CX‐5461 could inhibit pathological arterial remodelling caused by angioplasty and transplantation. In the present study,… Click to show full abstract
CX‐5461 is a novel selective RNA polymerase I (Pol I) inhibitor. Previously, we found that CX‐5461 could inhibit pathological arterial remodelling caused by angioplasty and transplantation. In the present study, we explored the pharmacological effects of CX‐5461 on experimental pulmonary arterial hypertension (PAH) and PAH‐associated vascular remodelling.
Keywords:
arterial hypertension;
rna polymerase;
pulmonary arterial;
novel selective;
associated vascular;
selective rna
Journal Title: British Journal of Pharmacology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Pharmacology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!